Form 4: Adaptimmune Therapeutics COO Sells Shares to Cover Tax Obligations

Adaptimmune Therapeutics' Chief Operating Officer, William C. Bertrand Jr., sold 5,584 American Depositary Shares (ADS) to cover tax obligations related to vested stock options.

Summary

• William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics, sold 5,584 American Depositary Shares (ADS).
• The sale was executed on January 17, 2025, at a weighted average price of $0.5808 per ADS.
• The sale was part of a 'Sell to Cover' transaction to satisfy tax withholding obligations and associated sale costs related to vested RSU-style share options.
• The ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589.
• Each ADS represents six ordinary shares of Adaptimmune Therapeutics.
• The options were granted on January 17, 2023, and have vested.
• After the sale, Bertrand still holds 7,510 ADSs from this transaction, in addition to 191,382 ADSs and options covering 13,421,994 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but is a normal part of company operations. The fact that the executive retains a significant number of shares is a positive sign.

Positives

• The transaction is a standard 'Sell to Cover' exercise, indicating a normal process for handling vested stock options.
• The COO retains a significant number of shares and options, suggesting continued alignment with the company's success.

Risks

• While the sale is for tax purposes, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

This is a routine transaction for a company with stock-based compensation, and is common in the biotech industry where stock options are a significant part of executive compensation.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice across publicly traded companies, particularly in the biotech sector where equity compensation is common.
• Similar transactions are regularly reported by executives at companies like Gilead Sciences, Amgen, and Biogen, as they exercise and sell shares to cover taxes.
• The volume of shares sold is relatively small compared to the total holdings of the executive, which is typical in these types of transactions.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the executive's confidence in the company.

Key Dates

Keywords

Adaptimmune Therapeutics, ADS, stock options, insider trading, Form 4, William C. Bertrand Jr., tax obligations, share sale, RSU